Pfizer (PFE) Q4 FY24 earnings call

Pfizer concluded a strong FY24, exceeding financial commitments and advancing strategic priorities, including the Seagen integration and commercial effectiveness improvements. The company is now shifting its emphasis to R&D productivity while maintaining focus on margin expansion and shareholder-friendly capital allocation. Management reaffirmed its FY25 guidance and outlined a clear path to deleveraging and balanced capital deployment, despite anticipated headwinds from the IRA.